Literature DB >> 24763136

Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution.

Daniel M Weinberger1, Eugene D Shapiro2.   

Abstract

Keywords:  conjugate vaccines; pneumococcus; pneumonia; prevention; vaccines

Mesh：

Substances：

Year:  2014        PMID： 24763136      PMCID： PMC4896592          DOI： 10.4161/hv.28962

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  13 in total

Review 1.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Authors:  Daniel A Scott; Steven F Komjathy; Branda T Hu; Sherryl Baker; Lois A Supan; Carol A Monahan; William Gruber; George R Siber; Stephen P Lockhart
Journal:  Vaccine       Date:  2007-06-26       Impact factor: 3.641

3.  Holiday spikes in pneumococcal disease among older adults.

Authors:  Nicholas D Walter; Thomas H Taylor; Scott F Dowell; Saundra Mathis; Matthew R Moore
Journal:  N Engl J Med       Date:  2009-12-24       Impact factor: 91.245

4.  Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Authors:  Anneke Steens; Marianne A Riise Bergsaker; Ingeborg S Aaberge; Karin Rønning; Didrik F Vestrheim
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

5.  Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

Authors:  Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-03       Impact factor: 3.164

6.  Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Authors:  Kenneth J Smith; Angela R Wateska; Mary Patricia Nowalk; Mahlon Raymund; J Pekka Nuorti; Richard K Zimmerman
Journal:  JAMA       Date:  2012-02-22       Impact factor: 56.272

7.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

8.  Effectiveness of pneumococcal polysaccharide vaccine in older adults.

Authors:  Lisa A Jackson; Kathleen M Neuzil; Onchee Yu; Patti Benson; William E Barlow; Annette L Adams; Christi A Hanson; Lisa D Mahoney; David K Shay; William W Thompson
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

9.  Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.

Authors:  Natasha B Halasa; Carlos G Grijalva; Patrick G Arbogast; Thomas R Talbot; Allen S Craig; Marie R Griffin; William Schaffner
Journal:  Pediatr Infect Dis J       Date:  2013-06       Impact factor: 2.129

10.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245
View more
  7 in total

1.  Association Between Local Pediatric Vaccination Rates and Patterns of Pneumococcal Disease in Adults.

Authors:  Sundia Cassandra Pingali; Joshua L Warren; Aimee M Mead; Nancy Sharova; Susan Petit; Daniel M Weinberger
Journal:  J Infect Dis       Date:  2015-08-26       Impact factor: 5.226

2.  Beyond efficacy: A career evaluating the effectiveness of vaccines.

Authors:  Eugene Shapiro
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

Review 3.  Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Authors:  Andrew D Wiese; Marie R Griffin; Carlos G Grijalva
Journal:  Expert Rev Vaccines       Date:  2019-03-20       Impact factor: 5.217

4.  The Influence of Influenza and Pneumococcal Vaccines on Community-Acquired Pneumonia (CAP) Outcomes Among Elderly Patients.

Authors:  Paul O Gubbins; Chenghui Li
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

Review 5.  Rationale and prospects for novel pneumococcal vaccines.

Authors:  Kristin Moffitt; Richard Malley
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

6.  The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study.

Authors:  Konosuke Morimoto; Motoi Suzuki; Tomoko Ishifuji; Makito Yaegashi; Norichika Asoh; Naohisa Hamashige; Masahiko Abe; Masahiro Aoshima; Koya Ariyoshi
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

7.  Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2016-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.